v3.26.1
DIVISION INFORMATION (SEGMENT REPORTING)
6 Months Ended
Jun. 30, 2026
DIVISION INFORMATION (SEGMENT REPORTING)  
DIVISION INFORMATION (SEGMENT REPORTING)

NOTE 17. DIVISION INFORMATION (SEGMENT REPORTING)

Historically, the Company’s activities were organized into three divisions, each of which was a reportable segment: High Intensity Focused Ultrasound (“HIFU”), Lithotripsy (“ESWL”) and Distribution services (“Distribution”). As described in Note 18,

on May 28, 2026 the Board of Directors approved a plan to exit the ESWL and Distribution segments to focus the Company exclusively on its HIFU business, and those segments are reported as discontinued operations for all periods presented. Following that classification, HIFU is the Company’s sole continuing reportable segment. The chief operating decision maker, the Company’s Chief Executive Officer, reviews segment operating income or loss for purposes of allocating resources and assessing performance. Segment information for all periods presented below has been recast to reflect the ESWL and Distribution segments as discontinued operations.

Three Months Ended June 30, 

Six Months Ended June 30, 

  ​ ​ ​

2026

  ​ ​ ​

2025

 

2026

  ​ ​ ​

2025

Operating loss

 

(8,012)

 

(6,547)

(15,378)

 

(12,856)

Financial (expense) income, net

 

(6,307)

 

(62)

(8,021)

 

(47)

Foreign currency exchange (losses) gains, net

 

(90)

 

310

52

 

(696)

Income tax (expense) benefit

 

(78)

 

(107)

(223)

 

(251)

Consolidated net loss

 

(14,487)

 

(6,406)

(23,570)

 

(13,850)

A summary of the Company’s operations by segment is presented below for the three and six months ended June 30, 2026, and 2025:

Three Months Ended

  ​ ​ ​

HIFU

  ​ ​ ​

Reconciling

  ​ ​ ​

Total

June 30, 2026

Division

Items

continuing

Sales of goods

 

9,527

 

9,527

Sales of RPPs & leases

 

2,758

 

2,758

Sales of spare parts and services

 

918

 

918

Total sales

 

13,203

 

13,203

External other revenues

 

 

Total revenues

 

13,203

 

13,203

Total cost of sales

 

(5,865)

 

(5,865)

Gross profit

 

7,338

 

7,338

R&D expenses

 

(2,317)

 

(2,317)

Selling and marketing expenses

 

(7,535)

 

(7,535)

General and administrative expenses

 

(3,334)

 

(2,185)

 

(5,519)

Total expenses

 

(13,186)

 

(2,185)

 

(15,371)

Operating income (loss) from operations

 

(5,848)

 

(2,185)

 

(8,033)

Total Assets

 

47,105

10,631

 

57,736

Net cash generated by (used in) investing activities

 

(1,253)

 

(1,253)

Non-current assets

 

15,533

 

15,533

Goodwill

 

735

 

735

Three Months Ended

  ​ ​ ​

HIFU

  ​ ​ ​

Reconciling

  ​ ​ ​

Total

June 30, 2025

Division

Items

continuing

Sales of goods

 

6,385

 

 

6,385

Sales of RPPs & leases

 

2,155

 

 

2,155

Sales of spare parts and services

 

969

 

 

969

Total sales

 

9,509

 

 

9,509

External other revenues

 

 

 

Total revenues

 

9,509

 

 

9,509

Total cost of sales

 

(4,646)

 

 

(4,646)

Gross profit

 

4,863

 

 

4,863

R&D expenses

 

(2,291)

 

 

(2,291)

Selling and marketing expenses

 

(5,295)

 

 

(5,295)

General and administrative expenses

 

(2,741)

 

(1,158)

 

(3,899)

Total expenses

 

(10,327)

 

(1,158)

 

(11,485)

Operating income (loss) from operations

 

(5,465)

 

(1,158)

 

(6,623)

Total Assets

 

48,266

13,070

 

61,336

Net cash generated by (used in) investing activities

 

(1,543)

 

(1,543)

Non-current assets

 

15,727

 

15,727

Goodwill

 

756

 

756

Six months ended

  ​ ​ ​

HIFU

  ​ ​ ​

Reconciling

  ​ ​ ​

Total

June 30, 2026

Division

Items

continuing

Sales of goods

 

17,782

 

17,782

Sales of RPPs & leases

 

5,250

 

5,250

Sales of spare parts and services

 

1,764

 

1,764

Total sales

 

24,796

 

24,796

External other revenues

 

 

Total revenues

 

24,796

 

24,796

Total cost of sales

 

(11,496)

 

(11,496)

Gross profit

 

13,300

 

13,300

R&D expenses

 

(4,784)

 

(4,784)

Selling and marketing expenses

 

(13,833)

 

(13,833)

General and administrative expenses

 

(6,475)

 

(4,265)

 

(10,740)

Total expenses

 

(25,092)

 

(4,265)

 

(29,357)

Operating income (loss) from operations

 

(11,792)

 

(4,265)

 

(16,057)

Total Assets

 

47,105

10,631

 

57,736

Net cash generated by (used in) investing activities

 

(1,680)

 

(1,680)

Non-current assets

 

15,533

 

15,533

Goodwill

 

735

 

735

Six months ended

  ​ ​ ​

HIFU

  ​ ​ ​

Reconciling

  ​ ​ ​

Total

June 30, 2025

Division

Items

continuing

Sales of goods

 

10,185

 

 

10,185

Sales of RPPs & leases

 

4,100

 

 

4,100

Sales of spare parts and services

 

1,724

 

 

1,724

Total sales

 

16,009

 

 

16,009

External other revenues

 

 

 

Total revenues

 

16,009

 

 

16,009

Total COS

 

(7,989)

 

 

(7,989)

Gross profit

 

8,020

 

 

8,020

R&D expenses

 

(4,648)

 

 

(4,648)

Selling and marketing expenses

 

(9,693)

 

 

(9,693)

G&A expenses

 

(4,784)

 

(2,262)

 

(7,046)

Total expenses

 

(19,126)

 

(2,262)

 

(21,388)

Operating income (loss) from operations

 

(11,106)

 

(2,262)

 

(13,368)

Total Assets

 

48,266

13,070

 

61,336

Net cash generated by (used in) investing activities

 

(2,742)

 

(2,742)

Non-current assets

 

15,727

 

15,727

Goodwill

 

756

 

756